Common Contracts
2 similar Research Collaboration, Option and License Agreement contracts by Exicure, Inc.
ContractResearch Collaboration, Option and License Agreement • May 5th, 2020 • New York
EX-10.24 6 a8-kaexhibit1024x11717.htm EXHIBIT 10.24 Exhibit 10.24 EXECUTION VERSION RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT by and between EXICURE, INC. and PURDUE PHARMA L.P. THE COMPANY HAS REQUESTED AN ORDER FROM THE SECURITIES AND EXCHANGE COMMISSION (THE “COMMISSION”) PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, GRANTING CONFIDENTIAL TREATMENT TO SELECTED PORTIONS. ACCORDINGLY, THE CONFIDENTIAL PORTIONS HAVE BEEN OMITTED FROM THIS EXHIBIT, AND HAVE BEEN FILED SEPARATELY WITH THE COMMISSION. OMITTED PORTIONS ARE INDICATED IN THIS EXHIBIT WITH “*****”. TABLE OF CONTENTS
RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT by and between EXICURE, INC. and PURDUE PHARMA L.P.Research Collaboration, Option and License Agreement • November 7th, 2017 • Exicure, Inc. • Pharmaceutical preparations • New York
This RESEARCH COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 2nd, 2016 (the “Effective Date”) by and between EXICURE, INC., a Delaware corporation having an address at 8045 Lamon Ave, Skokie, Illinois 60077, United States of America (“Licensor”), and PURDUE PHARMA L.P., a Delaware limited partnership having an address at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901, United States of America (“Licensee”). Licensor and Licensee are sometimes referred to individually as a “Party” and collectively as the “Parties.”
